Select outcomes.

Therapeutic Lu-177-PSMA resulted in better PSA response than cabazitaxel among 200 men with docetaxel-treated metastatic castrate-resistant prostate cancer in the phase 2 TheraP trial, but the kicker is they could have no evidence of FDG-positive/PSMA-negative disease on imaging. | Hofman, ASCO 2020